Rapydan, a medicated plaster, is manufactured by Eusa Pharma. The easy-to-use plaster works by combining two local anesthetic agents (lidocaine and tetracaine) with a breakthrough controlled heat-assisted drug delivery (CHADD) system and was licensed from Zars Pharma.
The novel CHADD system combined with the choice of the two local anesthetic agents enables Rapydan’s fast onset of action. Rapydan is indicated for surface anesthesia of the normal intact skin in connection with needle puncture in adults and children from three years of age; it can also be used in cases of superficial surgical procedures on normal intact skin in adults.
Janet Greeson, CEO of Samaritan, said: “We are very familiar with the Greek market and believe this is an important drug that will play a prominent role in treating surface anesthesia.”